It turned out that rate of cost to selling price of multinational pharmaceutical companies was average 66.6%

According to the 2013 audit report of 33 multinational pharmaceutical companies, it turned out that their rate of cost to selling price was average 66.6%. This figure is about 8% higher than that of 44 domestic listed pharmaceutical companies (58.7%), and 77 non-listed pharmaceutical companies (58.1%).

Roche Korea recorded the highest rate of cost to selling price of 82.2%, followed by the sam...